![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Wadsworth Center, New York State Department of Health, and School of Public Health, State University of New York at Albany, Albany, New York (X.Z., Q.-Y.Z., D.L., T.S., Y.W., G.L., J.G., X.D.);Qilu Hospital of Shandong University, Jinan, Shandong, China (Y.C.); and Givaudan Fragrance Research, Zurich, Switzerland (B.S.)
Despite recent progress in the identification and characterization of numerous nasal biotransformation enzymes in laboratory animals, the expression of biotransformation genes in human nasal mucosa remains difficult to study. Given the potential role of nasal biotransformation enzymes in the metabolism of airborne chemicals, including fragrance compounds and therapeutic agents, as well as the potential interspecies differences between laboratory animals and humans, it would be highly desirable to identify those biotransformation genes that are expressed in human nasal mucosa. In this study, a global gene expression analysis was performed to compare biotransformation enzymes expressed in human fetal and adult nasal mucosa to those expressed in liver. The identities of a list of biotransformation genes with apparently nasal mucosa-selective expression were subsequently confirmed by RNA-polymerase chain reaction (PCR) and DNA sequencing of the PCR products. Further quantitative RNA-PCR experiments indicated that, in the fetus, aldehyde dehydrogenase 6 (ALDH6), CYP1B1, CYP2F1, CYP4B1, and UDP glucuronosyltransferase 2A1 are expressed preferentially in the nasal mucosa and that ALDH7, flavin-containing monooxygenase 1, and glutathione S-transferase P1 are at least as abundant in the nasal mucosa as in the liver. The nasal mucosal expression of CYP2E1 was also detected. These findings provide a basis for further explorations of the metabolic capacity of the human nasal mucosa for xenobiotic compounds.
This article has been cited by other articles:
![]() |
Y. Mu, M. M. Klamerus, T. M. Miller, L. C. Rohan, S. H. Graham, and S. M. Poloyac Intravenous Formulation of N-Hydroxy-N'-(4-n-butyl-2-methylphenyl)formamidine (HET0016) for Inhibition of Rat Brain 20-Hydroxyeicosatetraenoic Acid Formation Drug Metab. Dispos., November 1, 2008; 36(11): 2324 - 2330. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Court, S. Hazarika, S. Krishnaswamy, M. Finel, and J. A. Williams Novel Polymorphic Human UDP-glucuronosyltransferase 2A3: Cloning, Functional Characterization of Enzyme Variants, Comparative Tissue Expression, and Gene Induction Mol. Pharmacol., September 1, 2008; 74(3): 744 - 754. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miyazawa, M. Gallagher, G. Preti, and P. M. Wise Synergistic Mixture Interactions in Detection of Perithreshold Odors by Humans Chem Senses, April 1, 2008; 33(4): 363 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Wise, S. E. Toczydlowski, and C. J. Wysocki Temporal Integration in Nasal Lateralization of Homologous Alcohols Toxicol. Sci., September 1, 2007; 99(1): 254 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Jeffrey, M. J. Iatropoulos, and G. M. Williams Nasal Cytotoxic and Carcinogenic Activities of Systemically Distributed Organic Chemicals Toxicol Pathol, December 1, 2006; 34(7): 827 - 852. [Abstract] [Full Text] [PDF] |
||||